Oncologic Drugs Advisory Committee; Amendment of Notice, 37911 [2012-15393]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 122 / Monday, June 25, 2012 / Notices
Estimated Total Annual Burden
Hours: 9,256.
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Planning, Research and Evaluation, 370
L’Enfant Promenade SW., Washington,
DC 20447, Attn: ACF Reports Clearance
Officer. All requests should be
identified by the title of the information
collection. Email address:
infocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Fax: 202–395–7285,
email:
OIRA_SUBMISSION@OMB.EOP.GOV,
Attn: Desk Officer for the
Administration for Children and
Families.
FOR FURTHER INFORMATION CONTACT:
37911
would constitute a clearly unwarranted
invasion of personal privacy.
Food and Drug Administration
[Docket No. FDA–2012–N–0001]
Oncologic Drugs Advisory Committee;
Amendment of Notice
AGENCY:
Food and Drug Administration,
HHS.
erowe on DSK2VPTVN1PROD with NOTICES
ACTION:
Notice.
The Food and Drug Administration
(FDA) is announcing an amendment to
the notice of meeting of the Oncologic
Drugs Advisory Committee. This
meeting was announced in the Federal
Register of May 31, 2012 (77 FR 32125–
32126). The amendment is being made
to reflect a change in the Date and Time,
and Procedure portions of the
document. The Date and Time of the
meeting will change to July 24, 2012,
from 8 a.m. to 6 p.m. The Procedure
portion of the document has changed to
reflect an updated public participation
time of 10:30 a.m. to 11 a.m., and 4:30
p.m. to 5 p.m. There are no other
changes.
VerDate Mar<15>2010
14:55 Jun 22, 2012
Jkt 226001
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2012–15473 Filed 6–22–12; 8:45 am]
BILLING CODE 4160–01–P
BILLING CODE 4184–01–P
Dated: June 19, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–15393 Filed 6–22–12; 8:45 am]
[FR Doc. 2012–15389 Filed 6–22–12; 8:45 am]
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Cardiovascular Sciences.
Date: July 17–18, 2012.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Maqsood A Wani, DVM,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2114,
MSC 7814, Bethesda, MD 20892, 301–435–
2270, wanimaqs@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Fellowship:
Endocrinology, Metabolism, Nutrition and
Reproductive Sciences.
Date: July 18, 2012.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Dianne Camp, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, ROOM # 6164,
Bethesda, MD 20892, 301–435–1044,
campdm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 20, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
Robert Sargis,
Reports Clearance Officer.
Caleb Briggs, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2417, Silver Spring,
MD 20993–0002, 301–796–9001, FAX:
301–847–8533, ODAC@fda.hhs.gov, or
FDA Advisory Committee Information
Line, 1–800–741–8138 (301–443–0572
in the Washington, DC area), and follow
the prompts to the desired center or
product area. Please call the Information
Line for up-to-date information on this
meeting.
SUPPLEMENTARY INFORMATION: In the
Federal Register of May 31, 2012, FDA
announced that a meeting of the
Oncologic Drugs Advisory Committee
would be held on July 24, 2012. On page
32125, in the third column, the Date
and Time portion of the document is
changed to read as follows:
Date and Time: The meeting will be
held on July 24, 2012 from 8 a.m. to 6
p.m.
On page 32126, in the first column,
the third sentence in the Procedure
portion of the document is changed to
read as follows:
Procedure: Oral presentations from
the public will be scheduled between
approximately 10:30 a.m. to 11 a.m.,
and 4:30 p.m. to 5 p.m.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to the advisory committees.
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
E:\FR\FM\25JNN1.SGM
25JNN1
]]>Agencies
[Federal Register Volume 77, Number 122 (Monday, June 25, 2012)]
[Notices]
[Page 37911]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-15393]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0001]
Oncologic Drugs Advisory Committee; Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing an amendment
to the notice of meeting of the Oncologic Drugs Advisory Committee.
This meeting was announced in the Federal Register of May 31, 2012 (77
FR 32125-32126). The amendment is being made to reflect a change in the
Date and Time, and Procedure portions of the document. The Date and
Time of the meeting will change to July 24, 2012, from 8 a.m. to 6 p.m.
The Procedure portion of the document has changed to reflect an updated
public participation time of 10:30 a.m. to 11 a.m., and 4:30 p.m. to 5
p.m. There are no other changes.
FOR FURTHER INFORMATION CONTACT: Caleb Briggs, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, FAX: 301-847-8533, ODAC@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), and follow the prompts to the desired center or
product area. Please call the Information Line for up-to-date
information on this meeting.
SUPPLEMENTARY INFORMATION: In the Federal Register of May 31, 2012,
FDA announced that a meeting of the Oncologic Drugs Advisory Committee
would be held on July 24, 2012. On page 32125, in the third column, the
Date and Time portion of the document is changed to read as follows:
Date and Time: The meeting will be held on July 24, 2012 from 8
a.m. to 6 p.m.
On page 32126, in the first column, the third sentence in the
Procedure portion of the document is changed to read as follows:
Procedure: Oral presentations from the public will be scheduled
between approximately 10:30 a.m. to 11 a.m., and 4:30 p.m. to 5 p.m.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: June 20, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2012-15393 Filed 6-22-12; 8:45 am]
BILLING CODE 4160-01-P
